Published in Cancer Weekly, April 8th, 2008
for presentation at the April meeting of the American Academy of Cancer
Research. -- Following the completion of enrollment in the Phase 1/2a trial of its
lead clinical candidate RAV12 in mid-February, Raven announced on March
11th that the study results had been accepted for presentation at the
American Society of Clinical Oncology in May. -- On March 13th, Raven announced that it had initiated a Phase 2 study of
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly